tiprankstipranks
Trending News
More News >
Cross Country Healthcare (CCRN)
NASDAQ:CCRN

Cross Country Healthcare (CCRN) AI Stock Analysis

Compare
266 Followers

Top Page

CCRN

Cross Country Healthcare

(NASDAQ:CCRN)

Select Model
Select Model
Select Model
Neutral 48 (OpenAI - 4o)
Rating:48Neutral
Price Target:
$8.00
▼(-5.77% Downside)
The overall stock score is primarily impacted by weak financial performance and bearish technical indicators. The negative P/E ratio and lack of dividend yield further weigh on the valuation. Corporate events provide a mixed outlook, with leadership changes seen positively but the failed merger impacting negatively.

Cross Country Healthcare (CCRN) vs. SPDR S&P 500 ETF (SPY)

Cross Country Healthcare Business Overview & Revenue Model

Company DescriptionCross Country Healthcare (CCRN) is a leading provider of healthcare staffing and workforce solutions, specializing in the recruitment and placement of healthcare professionals across various sectors, including nursing, allied health, and physician services. The company operates primarily in the temporary staffing market, offering a range of services such as travel nursing, per diem staffing, and recruitment process outsourcing. With a focus on meeting the dynamic needs of healthcare facilities, CCRN leverages technology and deep industry expertise to deliver high-quality staffing solutions that enhance patient care.
How the Company Makes MoneyCross Country Healthcare generates revenue primarily through its staffing services, which include travel nursing, per diem staffing, and other workforce solutions. The company charges healthcare facilities for the placement of temporary and permanent staff, earning a markup on the salaries of the healthcare professionals it places. Additional revenue streams include recruitment process outsourcing and managed services provider solutions. Significant partnerships with healthcare institutions and organizations enhance its ability to fill staffing needs efficiently. The demand for temporary healthcare staffing, driven by factors such as seasonal fluctuations, increased patient volumes, and workforce shortages, contributes to consistent revenue generation for CCRN.

Cross Country Healthcare Earnings Call Summary

Earnings Call Date:Nov 06, 2024
(Q3-2024)
|
% Change Since: |
Next Earnings Date:Feb 25, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted positive growth in home care, physician staffing, and education segments, along with strong financial management. However, significant declines in revenue and ongoing margin pressures in the Travel Nursing & Allied segment present notable challenges.
Q3-2024 Updates
Positive Updates
Home Care Staffing Growth
Home care staffing saw a 13% year-over-year increase in the third quarter, with expectations for mid-teens growth in the fourth quarter. The number of PACE programs has doubled since the acquisition in 2021.
Physician Staffing Expansion
Physician Staffing grew 4% sequentially and 10% year-over-year. The business has doubled in size since late 2022 and is expected to continue growing in double digits in 2024.
Education Business Performance
The education business is approaching $100 million on an annualized run rate with expected continued mid to high single-digit growth.
Intellify Platform Implementation
The company renewed its largest MSP customer under a multi-year agreement and has nearly completed client conversion to the Intellify platform.
Share Buyback and Financial Strength
Bought back 800,000 shares worth $12 million in the third quarter, with a strong cash position of $64 million and no outstanding debt.
Negative Updates
Revenue Decline
Consolidated revenue for the third quarter was down 7% sequentially and 29% year-over-year, primarily due to declines in Travel Nursing & Allied.
Gross Margin Pressure
Gross margin decreased to 20.4%, down 160 basis points year-over-year due to bill pay spread compression in the travel business.
Travel Nursing Challenges
Travel Nursing saw a decline of 11% sequentially and 41% year-over-year, with ongoing challenges in bill and pay rate alignment.
SG&A Expenses
Selling, general, and administrative expenses were down 22% year-over-year but were impacted by reductions in headcount.
Company Guidance
During the third quarter 2024 earnings call for Cross Country Healthcare, key guidance metrics were discussed for the upcoming fourth quarter. The company projects revenue to range between $300 million and $310 million, with an anticipated adjusted EBITDA of $11 million to $13 million, reflecting ongoing gross margin pressures due to competitive compensation packages affecting bill pay spreads. Despite a 7% sequential decline in third-quarter revenue to $315 million, there was a notable 20% increase in order volume entering the fourth quarter. The Physician Staffing segment grew 4% sequentially and 10% year-over-year, while Home Care Staffing experienced a 13% year-over-year increase. The company highlighted an anticipated regrowth in Travel Nursing & Allied as market conditions improve. Additionally, Cross Country Healthcare bought back 800,000 shares for approximately $12 million and plans to focus on strategic investments and M&A opportunities, maintaining a strong cash position with $64 million and no outstanding debt.

Cross Country Healthcare Financial Statement Overview

Summary
Income Statement
Balance Sheet
Cash Flow
Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Cross Country Healthcare Technical Analysis

Technical Analysis Sentiment
Negative
Last Price8.49
Price Trends
50DMA
9.91
Negative
100DMA
11.59
Negative
200DMA
12.56
Negative
Market Momentum
MACD
-0.42
Negative
RSI
39.98
Neutral
STOCH
51.40
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCRN, the sentiment is Negative. The current price of 8.49 is above the 20-day moving average (MA) of 8.18, below the 50-day MA of 9.91, and below the 200-day MA of 12.56, indicating a neutral trend. The MACD of -0.42 indicates Negative momentum. The RSI at 39.98 is Neutral, neither overbought nor oversold. The STOCH value of 51.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CCRN.

Cross Country Healthcare Peers Comparison

Overall Rating
UnderperformOutperform
Sector (―)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
$1.42B148.531.29%68.17%-85.42%
61
Neutral
$464.04M1.380.74%
57
Neutral
$743.53M-42.48-6.86%12.48%-9.28%
50
Neutral
$601.18M-2.17-35.90%-11.42%-617.31%
48
Neutral
$268.96M-17.00-3.76%-22.14%-787.87%
46
Neutral
$374.66M-1.16-73.31%5.21%5.21%
* Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CCRN
Cross Country Healthcare
8.21
-9.98
-54.87%
AMN
AMN Healthcare Services
15.65
-11.96
-43.32%
CYH
Community Health
3.35
0.34
11.30%
ASTH
Astrana Health
28.22
-2.06
-6.80%
INNV
InnovAge Holding
5.48
1.86
51.38%
AGL
Agilon Health
0.90
-1.98
-68.65%

Cross Country Healthcare Corporate Events

Business Operations and StrategyExecutive/Board Changes
Cross Country Healthcare Appoints New CEO Kevin C. Clark
Positive
Dec 15, 2025

On December 15, 2025, Cross Country Healthcare announced the departure of John A. Martins as President and CEO, effective December 14, 2025. Kevin C. Clark, the company’s co-founder and current Chairman, has been appointed as the new President and CEO. This leadership change is seen as a strategic move to usher in a new era of growth and innovation, particularly following the termination of a transaction with Aya Healthcare. Clark’s extensive experience in the healthcare staffing industry is expected to drive the company towards sustainable, long-term profitable growth.

The most recent analyst rating on (CCRN) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Cross Country Healthcare stock, see the CCRN Stock Forecast page.

Executive/Board ChangesShareholder Meetings
Cross Country Healthcare Holds Annual Stockholders Meeting
Neutral
Dec 11, 2025

On December 9, 2025, Cross Country Healthcare held its Annual Meeting of Stockholders where several key proposals were voted on. The stockholders approved the election of directors for a one-year term, ratified the appointment of Deloitte & Touche as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and approved the compensation of named executive officers on an advisory basis.

The most recent analyst rating on (CCRN) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Cross Country Healthcare stock, see the CCRN Stock Forecast page.

Business Operations and StrategyStock BuybackM&A Transactions
Cross Country Healthcare Ends Merger with Aya Holdings
Negative
Dec 4, 2025

On December 4, 2025, Cross Country Healthcare announced the termination of its merger agreement with Aya Holdings II Inc. due to the failure to meet the merger’s consummation deadline, partly caused by an extended FTC review period. As a result, Aya Healthcare will pay a $20 million termination fee to Cross Country Healthcare. Despite the setback, Cross Country Healthcare remains focused on its strategic goals, emphasizing its operational resilience and financial strength, and plans to commence share repurchases under its existing $40 million authorization.

The most recent analyst rating on (CCRN) stock is a Hold with a $10.50 price target. To see the full list of analyst forecasts on Cross Country Healthcare stock, see the CCRN Stock Forecast page.

Business Operations and StrategyFinancial DisclosuresM&A Transactions
Cross Country Healthcare Reports Q3 2025 Financial Results
Neutral
Nov 12, 2025

Cross Country Healthcare announced its financial results for the third quarter of 2025, revealing a consolidated revenue of $250.1 million, a 21% decrease year-over-year. Despite a net loss of $4.8 million, the company reported strong performance in its Homecare Staffing segment, with a 29% revenue growth over the prior year. The company maintained a healthy balance sheet with $99 million in cash and no debt, and positive cash flow from operations of $20 million for the quarter. As the company awaits the completion of its merger with Aya Healthcare, it continues to focus on expanding and renewing contracts, with over $400 million in contract value secured.

The most recent analyst rating on (CCRN) stock is a Hold with a $13.00 price target. To see the full list of analyst forecasts on Cross Country Healthcare stock, see the CCRN Stock Forecast page.

M&A TransactionsShareholder Meetings
Cross Country Healthcare Sets Stockholder Proposal Deadline
Neutral
Sep 30, 2025

On September 25, 2025, Cross Country Healthcare‘s Board of Directors announced that the 2025 Annual Meeting of Stockholders is scheduled for December 9, 2025, unless the pending merger with Aya Healthcare is completed beforehand. If the merger is finalized as expected in the fourth quarter of 2025, Cross Country Healthcare will become a wholly owned subsidiary of Aya Healthcare, and the Annual Meeting will not occur. The company has set an October 10, 2025, deadline for stockholder proposals and nominations, with specific guidelines for submission.

The most recent analyst rating on (CCRN) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Cross Country Healthcare stock, see the CCRN Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 19, 2025